Glucose Monitoring for Type 2 Diabetes on Basal Insulin
For patients with type 2 diabetes on basal insulin, monitor fasting blood glucose daily during titration (every 2-3 days) until the target of <110 mg/dL is achieved, then reduce frequency based on stability of control. 1
Monitoring Schedule During Titration
Active Titration Phase
- Daily fasting blood glucose measurements are essential when initiating or adjusting basal insulin 1
- Titrate basal insulin every 2-3 days based on fasting glucose values 1
- For longer-acting insulins (glargine U300, degludec), titrate every 3-5 days due to longer time to steady state 1
Titration Algorithm
The 2023 AACE guidelines provide a clear, structured approach 1:
If fasting glucose is:
- >180 mg/dL: Increase insulin dose by 20%
- 140-180 mg/dL: Increase by 10%
- 110-139 mg/dL: Increase by 1 unit
- <70 mg/dL: Decrease by 10-20%
- <40 mg/dL: Decrease by 20-40%
Target Fasting Glucose Values
The primary target is fasting glucose <110 mg/dL without hypoglycemia 1. This is more specific than the broader preprandial target of 80-130 mg/dL mentioned in general diabetes guidelines 2.
For older adults or those with comorbidities, a more relaxed target of 90-150 mg/dL may be appropriate 3, 4, 3.
After Achieving Stable Control
Once fasting glucose stabilizes within target range:
- Reduce monitoring frequency to intermittent checks 5
- Continue some ongoing monitoring, with frequency determined by clinical context (medication regimen, A1C, patient capability) 5
- For patients on basal insulin alone with stable A1C at goal, monitoring 1-2 times daily (fasting plus one additional check) is often sufficient 6
When to Increase Monitoring
Resume more frequent monitoring during:
- Illness or intercurrent medical conditions 5
- Symptoms of hyperglycemia or hypoglycemia 6
- Medication adjustments 5
- If A1C rises above target despite fasting glucose at goal (suggests need for postprandial monitoring) 2
Continuous Glucose Monitoring Option
Real-time CGM or intermittently scanned CGM should be offered to adults on basal insulin who can use the devices safely 5. This represents a higher level of evidence (Level A for rtCGM, Level B for isCGM) and can reduce monitoring burden while improving glycemic awareness.
Critical Safety Points
- Hypoglycemia threshold: Any glucose <70 mg/dL requires insulin dose reduction 1
- Patients must be educated on hypoglycemia recognition and treatment before insulin initiation 1
- Glucagon should be prescribed for all patients at increased hypoglycemia risk 2
The evidence strongly supports that fasting glucose monitoring is the cornerstone for basal insulin management, as basal insulin primarily affects fasting values. The specific <110 mg/dL target from the most recent AACE guidelines 1 provides clearer direction than older, broader ranges and is associated with optimal A1C reduction without excessive hypoglycemia risk 7.